Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort.
To assess time trends in incidence of AIDS illnesses in Australia, a retrospective cohort of people diagnosed with AIDS from January 1, 1983 to December 31, 1994 in three HIV medicine units in Sydney, Melbourne, and Perth was established. Data on initial and subsequent AIDS illnesses were available for 2580 AIDS cases, or 45% of Australian AIDS notifications over the study period. Males represented 97.2% of the cohort, and HIV exposure category was homosexual contact for 89.9%. Subcohorts were formed by interval of AIDS diagnosis: 1983 through 1987, 1988 through 1990, and 1991 through 1994, with estimation of cumulative risk for each AIDS illness by the Kaplan-Meier method. The cumulative risk declined for Pneumocystis carinii pneumonia (PCP) (p < 0.0001) and for Kaposi's sarcoma (KS) (p < 0.0001); PCP cumulative risk estimates 2 years following AIDS diagnosis were 70% for people diagnosed with AIDS in 1983 through 1987 and 48% in 1991 through 1994, and KS cumulative risk estimates 2 years following AIDS diagnosis were 44% in 1983 through 1987 and 32% in 1991 through 1994. In contrast, cumulative risk increased from 34% to 40% for cytomegalovirus (CMV) disease (p = 0.005), from 47% to 50% for Mycobacterium avium complex (MAC) (p < 0.0001), and from 26% to 33% for esophageal candidiasis (p < 0.0001). Corresponding to this changing spectrum of AIDS illness has been an increase in severity of immunodeficiency at AIDS, with median CD4 cell count declining from 54 cells/mm3 in 1983 through 1987 to 34/mm3 in 1991 through 1994 (p = 0.002).
Dore
G J
GJ
National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia.
Hoy
J F
JF
Mallal
S A
SA
Li
Y
Y
Mijch
A M
AM
French
M A
MA
Cooper
D A
DA
Kaldor
J M
JM
D015526:AIDS Dementia Complex / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000627:therapeutic use; D001315:Australia / Q000453:epidemiology; D018791:CD4 Lymphocyte Count; D015331:Cohort Studies; D003453:Cryptococcosis / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D003586:Cytomegalovirus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D011020:Pneumonia, Pneumocystis / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D012307:Risk Factors; D012514:Sarcoma, Kaposi / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality; D015996:Survival Rate / Q000639:trends; D014123:Toxoplasmosis / Q000188:drug therapy / Q000453:epidemiology / Q000401:mortality
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents